ClinicalTrials.gg
RecruitingNCT07112287MyeloGenUpdated Apr 24, 2026

Germline Testing for Predisposition to Myeloid Malignancies

An interventional study of MyeloGen Gene Panel in Myeloid Malignancy, Genetic Predisposition to Disease and Myeloid Hematological Malignancies, sponsored by Christopher Reilly. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-24.

Sponsored by Christopher Reilly · Not applicable, Interventional, and Screening

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 87 studies in Genetic Predisposition to Disease with a site in United States — 37 open to participants now, 46 under way, none of them phase 3. Genetic Predisposition to Disease · United States.

Planned enrollment
21st of 37
200 · median 225
Started
2025
with 3 others
No phase
30 of 87
8 open now
Primary completion
2030-04
later than 33 of 45 live
Registered
79th of 87
by date

Among the 87 studies in Genetic Predisposition to Disease with a site in United States, this one is the 21st largest by planned enrollment of the 37 interventional ones that give a count, is one of 4 that started in 2025, is one of 30 with no phase, reaches primary completion later than 33 of the 45 other live ones, and was the 79th registered.

Genetic Predisposition to Disease

242 studies on the registry are indexed under Genetic Predisposition to Disease; 96 are open to participants now.

Browse Genetic Predisposition to Disease studies →

Open to participants now

37 of the 87 studies in Genetic Predisposition to Disease with a site in United States are open now. Recruiting first, the newest first:

31 more — sign in →

All 37 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 71 Genetic Predisposition to Disease studies recruiting now, 36 (51%) set no upper age limit and 28 (39%) stop at 75 or younger; 25 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 87 studies in Genetic Predisposition to Disease with a site in United States, or all of them as a file.
02

Study summary

The goal of this research study is to evaluate the feasibility of germline genetic testing using the investigational MyeloGen Gene Panel in adult participants diagnosed with myeloid malignancies.

Read the detailed description

This prospective, single arm study aims to evaluate the feasibility of germline genetic testing using the investigational MyeloGen Gene Panel in adult participants diagnosed with myeloid malignancies. Investigators hope to learn how to best incorporate routine genetic testing in clinical care for participants with blood cancers, regardless of personal or family history of blood cancer.

The research study procedures include screening for eligibility, in-clinic visits, questionnaires, and punch skin biopsies.

It is expected that about 200 people will take part in this research study.

The laboratory sponsor of this protocol is Broad Clinical Laboratory.

03

Conditions studied

  • Myeloid Malignancy
  • Genetic Predisposition to Disease
  • Myeloid Hematological Malignancies

Keywords

  • Myeloid Malignancies
  • Genetic Predisposition to Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age of 18 years or older
  • Participants must have confirmed myeloid OR bone marrow failure within the last 6 months prior to screening.
  • Ability to understand and provide a signed and completed consent document in English.

Exclusion criteria

Exclusion Criteria:

  • Participants who cannot safely undergo clinically indicated skin as adjudicated by the study team.
  • Participants who have previously undergone germline genetic testing for predisposition to myeloid
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    MyeloGen Germline Testing Group

    Enrolled participants will complete: * Baseline visit with questionnaires, educational video, and punch skin biopsy * Negative genetic test results notification via mail * Positive genetic results will be followed up by an appointment with a genetic counselor or physician * Post-results questionnaires * Follow up via medical records for up to 2 years from time of study consent.

    Device: MyeloGen Gene Panel

Interventions

  • DeviceMyeloGen Gene Panel

    The MyeloGen Gene Panel is investigational Germline genetic testing using skin fibroblasts.

    Also known as: Custom hereditary cancer gene panel

06

What researchers measure

Primary outcomes

  1. Successful Completion Rate

    Successful completion rate of germline genetic testing will be defined as the proportion of participants who return genetic test results within 10 weeks of study consent, which would require there be no excessive delays in obtaining a skin biopsy.

    Time frame: Up to 10 weeks

Secondary outcomes

  1. Number of Participants with Positive Results

    A "positive" result indicating a pathogenic or likely pathogenic variant was detected. This will also include Variants of Unknown Significance (VUSs) with supporting pathogenic criteria per American College of Medical Genetics guidelines (ACMG).

    Time frame: Up to 12 weeks

  2. Patient Reported Outcome of Germline Genetic Testing based on GST Survey

    Participants will complete the GST survey 1 (after the educational video and skin biopsy) and GST survey 2 between 45-60 days after disclosure of genetic test results. GST survey answers will be converted to a 5-point scale: 1- Disagree strongly, 2-Disagree, 3-Neither Agree or Disagree, 4-Agree, 5- Agree strongly.

    Time frame: Up to 60 days

  3. Number of Participants with an Identified Germline Predisposition on Generic Testing Who Haven't Met NCNN Guideline-based Germline Genetic Testing Recommendations

    NCCN guideline-based eligibility for germline genetic testing will be assessed using the following criteria and manual review of participants' medical record, 1) Participants with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) less than age 50, 2) Hypoplastic MDS regardless of age; 3) History of aplastic anemia, 4) Documented suspicion of a possible germline predisposition to myeloid malignancies.

    Time frame: Up to 12 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data can be shared no earlier than 1 year following the date of publication

Access criteria: Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Apr 2030, 52 months after the start.

Of 57 non-industry interventional studies with no phase under Genetic Predisposition to Disease, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 128. This study's planned 52 months is above that.

Counting every sponsor, half of 57 studies reached it within 36 months; a quarter within 18 and three quarters within 128.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 1, 2025
First posted
Aug 8, 2025
StartActual
Nov 10, 2025
Primary completionEst.
Apr 1, 2030
CompletionEst.
Apr 1, 2033
Last update
Apr 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07112287
Lead sponsor
Christopher Reilly
Collaborators
Broad Institute of MIT and Harvard
Responsible party
Christopher Reilly (Sponsor-Investigator, Dana-Farber Cancer Institute) — Sponsor-investigator
First posted
Aug 8, 2025
Start date
Nov 10, 2025
Primary completion
Apr 1, 2030 (estimated)
Completion
Apr 1, 2033 (estimated)
Last update
Apr 24, 2026

Study contacts

Christopher R Reilly, MD
Contact
Christopherr_reilly@dfci.harvard.edu
407-443-6243
Christopher R Reilly, MD
principal investigator · Dana-Farber Cancer Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion